Claus Cursiefen, Eric Viaud, Felix Bock, Bernard Geudelin, Antoine Ferry, Pavla Kadlecová, Michel Lévy, Salman Al Mahmood, Sylvie Colin, Eric Thorin, François Majo, Beatrice Frueh, Frank Wilhelm, Tobias Meyer-Ter-Vehn, Gerd Geerling, Daniel Böhringer, Thomas Reinhard, Daniel Meller, Uwe Pleyer, Björn Bachmann, Berthold Seitz
OBJECTIVE: Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding phase II study. We aimed to confirm these results in a phase III study and investigated a potential clinical benefit on visual acuity (VA), quality of life (QoL), and need for transplantation. DESIGN: Multicenter, double-masked, randomized, placebo-controlled phase III study. PARTICIPANTS: Analysis of 69 patients with keratitis-related progressive corneal neovascularization randomized to aganirsen (34 patients) or placebo (35 patients)...
September 2014: Ophthalmology